**Table S1. Patient characteristics**

|  |  |
| --- | --- |
| **Characteristic**  | **No. (% or range)** |
| **Age (year)** ≤ 60 > 60 | 41 (9 – 80)241 (88.9)30 (11.1) |
| **Gender** |  |
|  Male | 173 (63.8) |
|  Female | 98 (36.2) |
| **B symptoms** No Yes  | 138 (50.9)133 (49.1) |
| **LDH level** Normal  Higher than normal | 198 (73.1)73 (26.9) |
| **ECOG PS** 0-1 2-4 | 247 (91.1)24 (8.9) |
| **Local invasiveness** No Yes | 107 (39.5)164 (60.5) |
| **Tumor extent** |  |
|  Confined to the head and neck | 230 (84.9) |
|  Distal metastasis  | 41 (15.1) |
| **Regional lymph node involvement** |  |
|  No | 215 (79.3) |
|  One side | 31 (11.4) |
|  Both sides | 25 (9.2) |
| **Splenomegaly**\* No Yes | 172 (63.5)99 (36.5) |
| **Pretreatment plasma EBV-DNA (copy/mL)**† ≤ 500 > 500 | 48 (37.5)80 (62.5) |
| **AA stage** |  |
|  I | 190 (70.1) |
|  II | 46 (17.0) |
|  III | 9 (3.3) |
|  IV | 26 (9.6) |

\*Splenomegaly refers to splenic enlargement without abnormal density lesions and is not considered as tumor infiltration. †Data were available in 128 patients. Pretreatment plasma EBV-DNA level of > 500 copies/mL was identified as an adverse prognostic factor in a previous study[[1](#_ENREF_1)].

Abbreviations: LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance status ; AA, Ann Arbor.

1. Wang ZY, Liu QF, Wang H, Jin J, Wang WH, et al. (2012) Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 120: 2003-2010.